NASDAQ$XNCR
Xencor Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2024.
Xencor reported revenues of $17.0 million and a net loss of $66.0 million for the second quarter ended June 30, 2024. The company's cash, cash equivalents, and marketable debt securities totaled $585.0 million as of June 30, 2024. They expect to end 2024 with between $475 million and $525 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2027.
- Xencor is focused on developing first-in-class bispecific T-cell engagers and additional XmAb® candidates.
- Dose-escalation studies of XmAb819 and XmAb808 are on track to reach target dose levels by year end.
- XmAb541 is off to a strong clinical start with initial study enrollment.
- Xencor regained exclusive worldwide rights to plamotamab (CD20 x CD3).
Headline financials
Revenue & EPS history
Xencor · Revenue · Quarterly
$17M
Forward guidance
Xencor expects to end 2024 with between $475 million and $525 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.1%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.1%
Avg return
30 days after
48%
25 / 52 earnings
Positive
+11.3%
Q2 2018
Best reaction
-16.6%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -0.5% | -8.4% | |
| Q4 2025 | +1.5% | +4.1% | -3.3% | |
| Q3 2025 | -2.4% | +3.5% | +20.4% | |
| Q1 2025 | +0.2% | -4.6% | +12.3% | |
| Q3 2024 | +7.7% | +8.3% | +17.8% | |
| Q2 2024 | -6.9% | -16.4% | -13.3% | |
| Q1 2024 | -5.0% | -13.9% | -8.1% | |
| Q4 2023 | -11.9% | -7.9% | -14.5% | |
| Q3 2023 | -6.3% | -7.3% | +9.8% | |
| Q2 2023 | +2.8% | +1.4% | -4.6% | |
| Q1 2023 | -2.2% | -2.4% | -1.6% | |
| Q4 2022 | -3.2% | -6.1% | -18.3% | |
| Q3 2022 | +8.6% | +9.0% | +9.9% | |
| Q2 2022 | +2.3% | +1.4% | -8.5% | |
| Q1 2022 | -1.0% | -2.5% | -16.7% | |
| Q4 2021 | +1.3% | -2.4% | -12.3% | |
| Q3 2021 | -7.0% | -6.4% | -13.3% | |
| Q2 2021 | +2.9% | -2.3% | +7.8% | |
| Q1 2021 | -2.4% | -6.3% | -10.4% | |
| Q4 2020 | -1.3% | +0.3% | -10.8% | |
| Q3 2020 | -8.7% | -3.9% | -5.7% | |
| Q2 2020 | -3.2% | +1.0% | +6.6% | |
| Q1 2020 | +7.1% | +7.3% | -3.2% | |
| Q4 2019 | -8.8% | -7.6% | -18.2% | |
| Q3 2019 | -1.0% | -1.0% | +20.9% | |
| Q2 2019 | -16.6% | -15.6% | -18.9% | |
| Q1 2019 | +10.7% | +4.9% | -3.5% | |
| Q4 2018 | -3.1% | -0.8% | +1.3% | |
| Q3 2018 | +6.2% | -0.3% | +3.7% | |
| Q2 2018 | +11.3% | +10.0% | +10.1% | |
| Q1 2018 | -2.5% | +4.4% | +38.4% | |
| Q4 2017 | +4.8% | +0.9% | +2.6% | |
| Q3 2017 | +2.1% | +4.6% | +10.7% | |
| Q2 2017 | +4.7% | -3.9% | -1.9% | |
| Q1 2017 | -6.8% | -6.3% | -12.0% | |
| Q4 2016 | +7.6% | +5.5% | -5.6% | |
| Q3 2016 | -11.0% | -4.7% | +24.9% | |
| Q2 2016 | +9.4% | +16.0% | +10.7% | |
| Q1 2016 | -2.9% | — | — | |
| Q4 2015 | +11.2% | — | — | |
| Q3 2015 | +4.6% | — | — | |
| Q2 2015 | -2.2% | — | — | |
| Q1 2015 | -5.5% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q3 2013 | +3.6% | — | — | |
| Q2 2013 | +1.7% | — | — | |
| Q2 2014 | +2.6% | — | — | |
| Q4 2013 | -1.6% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro